Apoptosis and the treatment of breast cancer

Breast Disease

Volumn 15, Issue , 2002, Pages 71-82

  Cuello, Mauricio A ^a   Nau, Marion ^b   Lipkowitz, Stan ^b  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 6 BROMO 4 (1 CYANO 2 ETHOXY 2 OXOETHYL) 4H CHROMENE 3 CARBOXYLIC ACID ETHYL ESTER; ANTIMYCIN A1; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; APOPTOTIC PROTEASE ACTIVATING FACTOR 1; CASPASE 10; CASPASE 8; CASPASE 9; CISPLATIN; CYTOCHROME C; DACTINOMYCIN; ENZYME ANTIBODY; ENZYME INHIBITOR; FAS ANTIGEN; G 4259; GENESENSE; OBLIMERSEN; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN INHIBITOR; PROTEIN KINASE B; PROTEIN P53; SURVIVIN; TAMOXIFEN; TETROCARCIN A; TRASTUZUMAB; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; UNINDEXED DRUG;

APOPTOSIS; BREAST CANCER; CANCER CELL; CANCER MODEL; CANCER RADIOTHERAPY; CARCINOGENESIS; CELL DEATH; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL TRIAL; DOSE RESPONSE; DRUG POTENTIATION; GENE IDENTIFICATION; GENE MUTATION; GENETIC DISORDER; HORMONAL THERAPY; HUMAN; MOLECULAR BIOLOGY; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; STRUCTURE ACTIVITY RELATION;

EID: 0038449292     PISSN: 08886008     EISSN: None     Source Type: Journal    
DOI: 10.3233/BD-2002-15108     Document Type: Review

References (154)

1. J.F. Kerr, A.H. Wyllie and A.R. Currie, Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics, Br J Cancer 26 (1972), 239-257.
2. J.C. Reed, Mechanisms of apoptosis, Am J Pathol 157 (2000), 1415-1430.
3. A.H. Wyllie, J.F. Kerr and A.R. Currie, Cell death: the significance of apoptosis, Int Rev Cytol 68 (1980), 251-306.
4. J.C. Reed, Apoptosis and cancer: Strategies for Integrating Programmed Cell Death, Seminars in Hematology 37 (2000), 9-16.
5. K.C. Zimmermann, C. Bonzon and D.R. Green, The machinery of programmed cell death, Pharmacol Ther 92 (2001), 57-70,
6. D. Decaudin, I.I. Marzo, C. Brenner and G. Kroemer, Mitochondria in chemotherapy-induced apoptosis: A prospective novel target of cancer therapy (Review), Int J Oncol 12 (1998), 141-152.
7. J.C. Reed, J.M. Jurgensmeier and S. Matsuyama, Bcl-2 family proteins and mitochondria, Biochim Biophys Acta 1366 (1998),127-137.
8. W.C. Earnshaw, L.M. Martins and S.H. Kaufmann, Mammalian caspases: structure, activation, substrates, and functions during apoptosis, Annu Rev Biochem 68 (1999), 383-424.
9. Y. Shi, Mechanisms of caspase activation and inhibition during apoptosis, Mol Cell 9 (2002), 459-470.
10. G.S. Salvesen and G.S. Duckett, IAP proteins: blocking the road to death's door, Nat Rev Mol Cell Biol 3 (2002), 401-410,
11. U. Sartorius, I. Schmitz and P.H. Krammer, Molecular mechanisms of death-receptor-mediated apoptosis, Chem Biochem 2 (2001), 20-29.
12. A. Ashkenazi and V.M. Dixit, Death receptors: signaling and modulation, Science 281 (1998), 1305-1308.
13. A. Gross, J.M. McDonnell and S.J. Korsmeyer, BCL-2 family members and the mitochondria in apoptosis, Genes Dev 13 (1999), 1899-1911.
14. A. Suliman, A. Lam, R. Datta and R.K. Srivastava, Intracellular mechanisms of TRAIL: apoptosis through mitochondrial-dependent and -independent pathways, Oncogene 20 (2001), 2122-2133.
15. X.M. Sun, M. MacFarlane, J. Zhuang, B.B. Wolf, D.R. Green and G.M. Cohen, Distinct caspase cascades are initiated in receptor-mediated and chemical-induced apoptosis, J Biol Chem 274 (1999), 5053-5060.
16. M.A. Sheard, Ionizing radiation as a response-enhancing agent for CD95 -mediated apoptosis, Int J Cancer 96 (2001), 213-220.
17. J. Wen, N. Ramadevi, D. Nguyen, C. Perkins, E. Worthington and K. Bhalla, Antileukemic drugs increase death receptor 5 levels and enhance Apo-2L- induced apoptosis of human acute leukemia cells, Blood 96 (2000), 3900-3906.
18. S.J. Martin, Destabilizing Influences in Apoptosis. Sowing the Seeds of IAP Destruction, Cell 109 (2002), 793-796.
19. Y. Suzuki, Y. Nakabayashi and R. Takahashi, Ubiquitin-protein ligase activity of X-linked inhibitor of apoptosis protein promotes proteasomal degradation of caspase-3 and enhances its anti-apoptotic effect in Fas-induced cell death, Proc Natl Acad Sci USA 98 (2001), 8662-4667.
20. Y. Yang, S. Fang, J.P. Jensen, A.M. Weissman and J.D. Ashwell, Ubiquitin protein ligase activity of IAPs and their degradation in proteasomes in response to apoptotic stimuli, Science 288 (2000), 874-877.
21. H. Huang, C.A. Joazeiro, E. Bonfoco, S. Kamada, J.D. Leverson and T. Hunter, The inhibitor of apoptosis, cIAP2, functions as a ubiquitin-protein figase and promotes in vitro monoubiquitination of caspases 3 and 7, J Biol Chem 275 (2000), 26661-26664.
22. M. Jost, F.P. Gasparro, P.J. Jensen and U. Rodeck, Keratinocyte apoptosis induced by ultraviolet B radiation and CD95 ligation - differential protection through epidermal growth factor receptor activation and Bcl-x(L) expression, J Invest Dermatol 116 (2001), 860-866.
23. X. Wang, K.D. McCullough, T.F. Franke and N.J. Holbrook, Epidermal growth factor receptor-dependent Akt activation by oxidative stress enhances cell survival, J Biol Chem 275 (2000),14624-14631.
24. Y.S. Wan, Z.Q. Wang, Y. Shao, J.J. Voorhees and G.J. Fisher, Ultraviolet irradiation activates PI 3-kinase/AKT survival pathway via EGF receptors in human skin in vivo, Int J Oncol 18 (2001), 461-466.
25. C.M. van Golen, V.P. Castle and E.L. Feldman, IGF-I receptor activation and BCL-2 overexpression prevent early apoptotic events in human neuroblastoma, Cell Death Differ 7 (2000), 654-665.
26. J.P. Steinbach, P. Supra, H.J. Huang, W.K. Cavenee and M. Weller, CD95-mediated apoptosis of human glioma cells: modulation by epidermal growth factor receptor activity, Brain Pathol 12 (2002), 12-20.
27. S. Gibson, S. Tu, R. Oyer, S.M. Anderson and G.L. Johnson, Epidermal growth factor protects epithelial cells against Fas-induced apoptosis. Requirement for Akt activation, J Biol Chem 274 (1999), 17612-17618.
28. S.L. Moulder, F.M. Yakes, S.K. Muthuswamy, R. Bianco, J.F. Simpson and C.L. Arteaga, Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo, Cancer Res 61 (2001), 8887-8895.
29. M.M. Moasser, A. Basso, S.D. Averbuch and N. Rosen, The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells, Cancer Res 61 (2001), 7184-7188.
30. M. Cuello, S.A. Ettenberg, A.S. Clark et al., Downregulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2, Cancer Res 61 (2001), 4892-4900.
31. E. Yang and S.J. Korsmeyer, Molecular thanatopsis: a discourse on the BCL2 family and cell death, Blood 88 (1996), 386-401.
32. E.S. Hickman, M.C. Moroni and K. Helin, The role of p53 and pRB in apoptosis and cancer. Curr Opin Genet Dev 12 (2002), 60-66.
33. E.E. Balint and K.H. Vousden, Activation and activities of the p53 tumour suppressor protein, Br J Cancer 85 (2001), 1813-1823.
34. S. Pelengaris, M. Khan and G.I. Evan, Suppression of Myc-induced apoptosis in beta cells exposes multiple oncogenic properties of Myc and triggers carcinogenic progression, Cell 109 (2002), 321-334.
35. G.I. Evan and K.H. Vousden, Proliferation, cell cycle and apoptosis in cancer, Nature 411 (2001), 342-348.
36. D. Medina, The mammary gland: a unique organ for the study of development and turnorigenesis, J Mammary Gland Biol Neoplasia 1 (1996), 5-19.
37. R. Kumar, R.K. Vadlamudi and L. Adam, Apoptosis in mammary gland and cancer, Endocr Relat Cancer 7 (2000), 257-269.
38. J.S. Meyer, Cell proliferation in normal human breast ducts, fibroadenomas, and other ductal hyperplasias measured by nuclear labeling with tritiated thymidine. Effects of menstrual phase, age, and oral contraceptive hormones, Hum Pathol 8 (1977), 67-81.
39. J.R. Masters, J.O. Drife and J.J. Scarisbrick, Cyclic variation of DNA synthesis in human breast epithelium, J Natl Cancer Inst 58 (1977), 1263-1265.
40. D.J. Ferguson and T.J. Anderson, Morphological evaluation of cell turnover in relation to the menstrual cycle in the resting human breast, Br J Cancer 44 (1981), 177-181.
41. T.J. Ferguson DJ Anderson, Ultrastructural observations on cell death by apoptosis in the resting human breast, Virchows Arch [Pathol Anat] 393 (1981), 193-203.
42. P.M. Vogel, N.G. Georgiade, B.F. Fetter, F.S. Vogel and K.J. McCarty, The correlation of histologic changes in the human breast with the menstrual cycle, Am J Pathol 104 (1981), 23-34.
43. T.J. Anderson, D.J. Ferguson and G.M. Raab, Cell turnover in the resting human breast: influence of parity, contraceptive pill, age and laterality, Br J Cancer 46 (1982), 376-382.
44. J. Russo and I.H. Russo, Development pattern of human breast and susceptibility to carcinogenesis, Eur J Cancer Prev 3 (1993), 85-100.
45. M. Li, J. Hu, K. Heermeier, L. Hennighausen and P.A. Furth, Apoptosis and remodeling of mammary gland tissue during involution proceeds through p53-independent pathways, Cell Growth Differ 7 (1996), 13-20.
46. K. Heermeier, M. Benedict, M. Li, P. Furth, G. Nunez and L. Hennighausen, Bax and Bcl-xs are induced at the onset of apoptosis in involuting mammary epithelial cells, Mech Dev 56 (1996), 197-207.
47. M. Li, X. Liu, G. Robinson et al., Mammary-derived signals activate programmed cell death during the first stage of mammary gland involution, Proc Natl Acad Sci USA 94 (1997), 3425-3430.
48. R. Strange, T. Metcalfe, L. Thackray and M. Dang, Apoptosis in normal and neoplastic mammary gland development, Microsc Res Tech 52 (2001), 171-181.
49. S.L. Starcevic, C. Elferink and R.F. Novak, Progressive resistance to poptosis in a cell lineage model of human proliferative breast disease, J Natl Cancer Inst 93 (2001), 776-782.
50. M.M. Keane, S.A. Ettenberg, G.A. Lowrey, E.K. Russell and S. Lipkowitz, Fas expression and function in normal and malignant breast cell lines, Cancer Res 56 (1996), 4791-4798.
51. S.K. Muthuswamy, D. Li, S. Lelievre, M.J. Bissell and J.S. Brugge, ErbB2, but not ErbB1, reinitiates proliferation and induces luminal repopulation in epithelial acini, Nat Cell Biol 3 (2001), 785-792.
52. D.J. Slamon, G.M. Clark, S.G. Wong, W.J. Levin, A. Ullrich and W.L. McGuire, Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene, Science 235 (1987), 177-182.
53. M.J. van de Vijver, J.L. Peterse and W.J. Mooi et al., Neuprotein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer, N Engl J Med 319 (1988), 1239-1245.
54. M. van de Vijver, R. van de Bersselaar, P. Devilee, C. Cornelisse, J. Peterse and R. Nusse, Amplification of the neu (cerbB-2) oncogene in human mammmary tumors is relatively frequent and is often accompanied by amplification of the linked c-erbA oncogene, Mol Cell Biol 7 (1987), 2019-2023.
55. N.E. Hynes and D.F. Stern, The biology of erbB-2/neu/HER2 and its role in cancer, Biochim Biophys Acta 1198 (1994), 165-184.
56. A.S. Clark, K. West, S. Streicher and P.A. Dennis, Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells, Mol Cancer Ther 1 (2002), 707-717.
57. J. Brognard, A.S. Clark, Y. Ni and P.A. Dennis, Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation, Cancer Res 61 (2001), 3986-3997.
58. M.A. Shibata, I.G. Maroulakou, C.L. Jorcyk, L.G. Gold, J.M. Ward and J.E. Green, p53-independent apoptosis during mammary tumor progression in C3(1)/SV40 large T antigen transgenic mice: suppression of apoptosis during the transition from preneoplasia to carcinoma, Cancer Res 56 (1996), 2998-3003.
59. M.A. Shibata, M.L. Liu, M.C. Knudson et al., Haploid loss of bax leads to accelerated mammary tumor development in C3(1)/SV40-TAg transgenic mice: reduction in protective apoptotic response at the preneoplastic stage, Embo J 18 (1999), 2692-2701.
60. M. Li, B. Lewis, A.V. Capuco, B. Laucirica and P.A. Furth, WAP-TAg transgenic mice and the study of dysregulated cell survival, proliferation, and mutation during breast carcinogenesis, Oncogene 19 (2000), 1010-1019.
61. E.C. Mommers, P.J. van Diest, A.M. Leonhart, C.J. Meijer and J.P. Baak, Balance of cell proliferation and apoptosis in breast carcinogenesis, Breast Cancer Res Treat 58 (1999), 163-169.
62. D.J. Allan, A. Howell, S.A. Roberts et al., Reduction in apoptosis relative to mitosis in histologically normal epithelium accompanies fibrocystic change and carcinoma of the premenopausal human breast, J Pathol 167 (1992), 25-32.
63. G.L. Evan and T. Littlewood, A matter of life and cell death, Science 281 (1998), 1317-1322.
64. K. Tanaka, S. Iwamoto, G. Gon, T. Nohara, M. Iwamoto and N. Tanigawa, Expression of survivin and its relationship to loss of apoptosis in breast carcinomas, Clin Cancer Res 6 (2000), 127-134.
65. Herrnring C, Reimer T, Jeschke U, et al., Expression of the apoptosis-inducing ligands FasL and TRAIL in malignant and benign human breast tumors, Histochem Cell Biol 113 (2000),189-194.
66. L.S. Gutierrez, M. Eliza, T. Niven-Fairchild, F. Naftolin and G. Mor, The Fas/Fas-ligand system: a mechanism for immune evasion in human breast carcinomas, Breast Cancer Res Treat 54 (1999), 245-253.
67. J. Sjostrom, C. Blomqvist, K. von Boguslawski et al., The Predictive Value of bcl-2, bax, bcl-xL, bag-1, fas, and fasL for Chemotherapy Response in Advanced Breast Cancer, Clin Cancer Res 8 (2002), 811-816.
68. M.S. Shin, H.S. Kim, S.H. Lee et al., Mutations of tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) and receptor 2 (TRAIL-R2) genes in metastatic breast cancers, Cancer Res 61 (2001), 4942-4946.
69. S. Krajewski, M. Krajewska, B.C. Turner et al., Prognostic significance of apoptosis regulators in breast cancer, Endocr Relat Cancer 6 (1999), 29-40.
70. G.B. Mills, Y. Lu, X. Fang et al., The role of genetic abnormalities of PTEN and the phosphatidylinositol 3-kinase pathway in breast and ovarian tumorigenesis, prognosis, and therapy, Semin Oncol 28 (2001), 125-141.
71. D.H. Teng, R. Hu, H. Lin et al., MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines, Cancer Res 57 (1997), 5221-5225.
72. J. Li, C. Yen, D. Liaw et al., PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer, Science 275 (1997), 1943-1947.
73. M. Gasco, S. Shami and T. Crook, The p53 pathway in breast cancer, Breast Cancer Res 4 (2002), 70-76.
74. M. Vakkala, P. Paakko and Y. Soini, Expression of caspases 3, 6 and 8 is increased in parallel with apoptosis and histological aggressiveness of the breast lesion, Br J Cancer 81 (1999), 592-599.
75. J. Sjostrom, C. Blomqvist, K. von Boguslawski et al., The predictive value of bcl-2, bax, bcl-xL, bag-1, fas, and fasL for chemotherapy response in advanced breast cancer, Clin Cancer Res 8 (2002), 811-816.
76. J.J. Jager, R.L. Jansen, J.W. Arends et al., Anti-apoptotic phenotype is associated with decreased locoregional recurrence rate in breast cancer, Anticancer Res 20 (2000), 1269-1275.
77. C.A. Schmitt and S.W. Lowe, Apoptosis and therapy, J Pathol 187 (1999), 127-137.
78. A.M. Warri, R.L. Huovinen, A.M. Laine, P.M. Martikainen and P.L. Harkonen, Apoptosis in toremifene-induced growth inhibition of human breast cancer cells in vivo and in vitro, J Natl Cancer Inst. 85 (1993), 1412-1418.
79. R.R. Perry, Y. Kang and B. Greaves, Effects of tamoxifen on growth and apoptosis of estrogen-dependent and - independent human breast cancer cells, Ann Surg Oncol 2 (1995), 238-245.
80. D.M. Finucane, E. Bossy-Wetzel, N.J. Waterhouse, T.G. Cotter and D.R. Green, Bax-induced caspase activation and apoptosis via cytochrome c release from mitochondria is inhibitable by Bcl-xL, J Biol Chem 274 (1999), 2225-2233.
81. S. Hinz, A. Trauzold, L. Boenicke et al., Bcl-XL protects pancreatic adenocarcinoma cells against CD95- and TRAIL-receptor-mediated apoptosis, Oncogene 19 (2000), 5477-5486.
82. S.Y. Sun, P. Yue, J.Y. Zhou et al., Overexpression of BCL2 blocks TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in human lung cancer cells, Biochem Biophys Res Commun 280 (2001), 788-797.
83. B.C. Guo and Y.H. Xu, Bcl-2 over-expression and activation of protein kinase C suppress the trail-induced apoptosis in Jurkat T cells, Cell Res 11 (2001), 101-106.
84. A. Munshi, G. Pappas, T. Honda et al., TRAIL (APO-2L) induces apoptosis in human prostate cancer cells that is inhibitable by Bcl-2, Oncogene 20 (2001), 3757-3765.
85. B.A. Lamothe and B.B. Aggarwal, Ectopic expression of Bcl-2 and Bcl-xL inhibits apoptosis induced by TNF-related apoptosis-inducing ligand (TRAIL) through suppression of caspases-8, 7, and 3 and BID cleavage in human acute myelogenous leukemia cell line HL-60, J Interferon Cytokine Res 22 (2002), 269-279.
86. R.A. Olie and U. Zangemeister-Wittke, Targeting tumor cell resistance to apoptosis induction with antisense oligonucleotides: progress and therapeutic potential, Drug Resist Updat 4 (2001), 9-15.
87. D.E. Lopes de Menezes, N. Hudon, N. McIntosh and L.D. Mayer, Molecular and pharmacokinetic properties associated with the therapeutics of bel-2 antisense oligonucleotide G3139 combined with free and liposomal doxorubicin, Clin Cancer Res 6 (2000), 2891-2902.
88. A.P. Simoes-Wust, R.A. Olie, O. Gautschi et al., Bcl-xl antisense treatment induces apoptosis in breast carcinoma cells, Int J Cancer 87 (2000), 582-590.
89. O. Gautschi, S. Tschopp, R.A. Olie et al., Activity of a novel bcl-2/bcl-xL-bispecific antisense oligonucleotide against tumors of diverse histologic origins, J Natl Cancer Inst 93 (2001), 463-471.
90. A. Webb, D. Cunningham, F. Cotter et al., BCL-2 antisense therapy in patients with non-Hodgkin lymphoma, Lancet 349 (1997), 1137-1141.
91. H.X. Chen, J.L. Marshall, N. Trocky et al., A phase I study of Bcl-2 antisense G3139 (GENTA) and weekly docetaxel in patients with advanced breast cancer and other solid tumors, Proc Am Soc Clin Oncol 19 (2000), 692a.
92. B. Jansen, V. Wacheck, E. Heere-Ress et al., Chemosensitisation of malignant melanoma by BCL2 antisense therapy, Lancet 356 (2000), 1728-1733.
93. J.S. Waters, A. Webb, D. Cunningham et al., Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma, J Clin Oncol 18 (2000), 1812-1823.
94. K.N. Chi, M.E. Gleave, R. Klasa et al., A phase I dosefinding study of combined treatment with an antisense Bcl2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer, Clin Cancer Res 7 (2001), 3920-3927.
95. M.J. Morris, W.P. Tong, C. Cordon-Cardo et al., Phase I trial of BCL-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer, Clin Cancer Res 8 (2002), 679-683.
96. E.P. Holinger, T. Chittenden and R.J. Lutz, Bak BH3 peptides antagonize Bcl-xL function and induce apoptosis through cytochrome c-independent activation of caspases, J Biol Chem 274 (1999), 13298-13304.
97. T. Nakashima, M. Miura and M. Hara, Tetrocarcin A inhibits mitochondrial functions of Bcl-2 and suppresses its anti-apoptotic activity, Cancer Res 60 (2000), 1229-1235.
98. S.P. Tzung, K.M. Kim, G. Basanez et al., Antimycin A mimics a cell-death-inducing Bcl-2 homology domain 3, Nat Cell Biol 3 (2001), 183-191.
99. J.L. Wang, D. Liu, Z.J. Zhang et al., Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells, Proc Natl Acad Sci USA 97 (2000), 7124-7129.
100. W. Liu, J. Li and R.A. Roth, Heregulin regulation of Akt/protein kinase B in breast cancer cells, Biochem Biophys Res Commun 261 (1999), 897-903.
101. K.M. Ignatoski, T. Maehama, S.M. Markwart, J.E. Dixon, D.L. Livant and S.P. Ethier, ERBB-2 overexpression confers PI 3′ kinase-dependent invasion capacity on human mammary epithelial cells, Br J Cancer 82 (2000), 666-674.
102. G. Tari AMLopez-Berestein, Serum predominantly activates MAPK and akt kinases in EGFR- and ErbB2-over-expressing cells, respectively, Int J Cancer 86 (2000), 295-297.
103. B.P. Zhou, M.C. Hu, S.A. Miller et al., HER-2/neu blocks tumor necrosis factor-induced apoptosis via the Akt/NF-kappaB pathway, J Biol Chem 275 (2000), 8027-8031.
104. S.S. Bacus, D.A. Altomare, L. Lyass et al., AKT2 is frequently upregulated. in HER-2/neu-positive breast cancers and may contribute to tumor aggressiveness by enhancing cell survival, Oncogene 21 (2002), 3532-3540.
105. E. Tzahar and Y. Yarden, The ErbB-2/HER2 oncogenic receptor of adenocarcinomas: from orphanhood to multiple stromal ligands, Biochim Biophys Acta 1377 (1998), M25-37.
106. M.C. Hung and Y.K. Lau, Basic science of HER-2/neu: a review, Semin Oncol 26 (1999), 51-59.
107. V. Stambolic, A. Suzuki, J.L. de la Pompa et al., Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN, Cell 95 (1998), 29-39.
108. S.R. Datta, A. Brunet and M.E. Greenberg, Cellular survival: a play in three Akts, Genes Dev 13 (1999), 2905-2927.
109. A.H. Kim, G. Khursigara, X. Sun, T.F. Franke and M.V. Chao, Akt phosphorylates and negatively regulates apoptosis signal-regulating kinase 1, Mol Cell Biol 21 (2001), 893-901.
110. F. Li, E.J. Ackermann, C.F. Bennett et al., Pleiotropic cell-division defects and apoptosis induced by interference with survivin function, Nat Cell Biol 1 (1999), 461-466.
111. R.A. Olie, A.P. Simoes-Wust, B. Baumann et al., A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy, Cancer Res 60 (2000), 2805-2809.
112. J. Chai, C. Du, J.W. Wu, S. Kyin, X. Wang and Y. Shi, Structural and biochemical basis of apoptotic activation by Smac/DIABLO, Nature 406 (2000), 855-862.
113. K.M. Debatin, The role of CD95 system in chemotherapy, Drug Resist Updat 2 (1999), 85-90.
114. C.A. Smith, T. Farrah and R.G. Goodwin, The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death, Cell 76 (1994), 959-962.
115. J. Ogasawara, F.R. Watanabe, M. Adachi et al., Lethal effect of the anti-Fas antibody in mice, Nature 364 (1993), 806-809.
116. S.R. Wiley, K. Schooley, P.J. Smolak et al., Identification and characterization of a new member of the TNF family that induces apoptosis, Immunity 3 (1995), 673-682.
117. T. Gura, TRAIL kills cancer cells, but not normal cells, Science 277 (1997), 768.
118. G. Pan, J. Ni, Y.F. Wei, G. Yu, R. Gentz and V.M. Dixit, An antagonist decoy receptor and a death domain-containing receptor for TRAIL, Science 277 (1997), 815-818.
119. J.P. Sheridan, S.A. Marsters, R.M. Pitti et al., Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors, Science 277 (1997), 818-821.
120. I. Jeremias, I. Herr, T. Boehler and K.M. Debatin, TRAIL/Apo-2-ligand-induced apoptosis in human T cells, Eur J Immunol 28 (1998), 143-152.
121. B. Bonavida, C.P. Ng, A. Jazirehi, G. Schiller and Y. Mizutani, Selectivity of TRAIL-mediated apoptosis of cancer cells and synergy with drugs: the trail to non-toxic cancer therapeutics, Int J Oncol 15 (1999), 793-802.
122. L.E. French and J. Tschopp, The TRAIL to selective tumor death, Nat Med 5 (1999), 146-147.
123. M.M. Keane, S.A. Ettenberg, M.M. Nau, E.K. Russell and S. Lipkowitz, Chemotherapy augments TRAIL-induced apoptosis in breast cell lines, Cancer Res 59 (1999), 734-741.
124. H. Walczak, R.E. Miller, K. Ariail et al., Tumoricidal activity of tumor necrosis factor-related apoptosis- inducing ligand in vivo, Nat Med 5 (1999), 157-163.
125. M. Cuello, S.A. Ettenberg, M.M. Nan and S. Lipkowitz, Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells, Gynecol Oncol 81 (2001), 380-390.
126. A. Ashkenazi and V.M. Dixit, Apoptosis control by death and decoy receptors, Curr Opin Cell Biol 11 (1999), 255-260.
127. T.S. Griffith and D.H. Lynch, TRAIL: a molecule with multiple receptors and control mechanisms, Curr Opin Immunol 10 (1998), 559-563.
128. S.A. Marsters, R.A. Pitti, J.P. Sheridan and A. Ashkenazi, Control of apoptosis signaling by Apo2 ligand, Recent Prog Horm Res 54 (1999), 225-234.
129. W. Roth, S. Isenmann, U. Naumann et al., Locoregional Apo2L/TRAIL eradicates intracranial human malignant glioma xenografts in athymic mice in the absence of neurotoxicity, Biochem Biophys Res Commun. 265 (1999), 479-483.
130. I.F. Pollack, M. Erff and A. Ashkenazi, Direct stimulation of apoptotic signaling by soluble Apo2l/tumor necrosis factor-related apoptosis-inducing ligand leads to selective killing of glioma cells, Clin Cancer Res 7 (2001), 1362-1369.
131. D. Lawrence, Z. Shahrokh, S. Marsters et al., Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions, Nat Med 7 (2001), 383-385.
132. A. Ashkenazi, R.C. Pai, S. Fong et al., Safety and antitumor activity of recombinant soluble Apo2 ligand, J Clin Invest. 104 (1999), 155-162.
133. K. Ichikawa, W. Liu, L. Zhao et al., Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity, Nat Med 7 (2001), 954-960.
134. T.W. Salcedo, R.F. Alderson, S. Basu et al., TRM-1, a fully human TRAIL-R1 agonistic monoclonal antibody, displays in vitro and in vivo anti-tumor activity, Proceedings of the 93rd Annual Meeting of the AACR 43 (2002), 579.
135. J.D. Bretz, M. Rymaszewski, P.L. Arscott et al., TRAIL death pathway expression and induction in thyroid follicular cells, J Biol Chem 274 (1999), 23627-23632.
136. V. Snell, K. Clodi, S. Zhao et al., Activity of TNF-related apoptosis-inducing ligand (TRAIL) in haematological malignancies, Br J Haematol 99 (1997), 618-624.
137. X.D. Zhang, A. Franco, K. Myers, C. Cray, T. Nguyen and P. Hersey, Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma, Cancer Res 59 (1999), 2747-2753.
138. K. Kim, M.J. Fisher, S.Q. Xu and W.S. el-Deiry, Molecular determinants of response to TRAIL in killing of normal and cancer cells, Clin Cancer Res 6 (2000), 335-346.
139. J. Baselga, Herceptin alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer: pivotal trials, Oncology 61(Suppl 2) (2001), 14-21.
140. J. Baselga, D. Tripathy, J. Mendelsohn et al., Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer, Semin Oncol 26 (1999), 78-83.
141. D.J. Slamon, B. Leyland-Jones, S. Shak et al., Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2, N Engl J Med 344 (2001), 783-792.
142. K.H. Vousden, Activation of the p53 tumor suppressor protein, Biochim Biophys Acta 1602 (2002), 47-59.
143. M. Schuler and D.R. Green, Mechanisms of p53-dependent apoptosis, Biochem Soc Trans 29 (2001), 684-688.
144. K.H. Vousden and X. Lu, Live or let die: the cell's response to p53, Nat Rev Cancer 2 (2002), 594-604.
145. M. Hollstein, D. Sidransky, B. Vogelstein and C.C. Harris, p53 mutations in human cancers. Science 1991; 253: 49-53.
146. R.J. Steele, A.M. Thompson, P.A. Hall and D.P. Lane, The p53 tumour suppressor gene, Br J Surg 85 (1998), 1460-1467.
147. B. Yang, J.R. Eshleman, N.A. Berger and S.D. Markowitz, Wild-type p53 protein potentiates cytotoxicity of therapeutic agents in human colon cancer cells, Clin Cancer Res 2 (1996), 1649-1657.
148. J.F. Ju, D. Banerjee, H.J. Lenz et al., Restoration of wildtype p53 activity in p53-null HL-60 cells confers multidrug sensitivity, Clin Cancer Res 4 (1998), 1315-1322.
149. B.A. Foster, H.A. Coffey, M.J. Morin and F. Rastinejad, Pharmacological rescue of mutant p53 conformation and function, Science 286 (1999), 2507-2510.
150. V.J. Bykov, N. Issaeva, A. Shilov et al., Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound, Nat Med 8 (2002), 282-288.
151. P. Chene, J. Fuchs, J. Bohn, C. Garcia-Echeverria, P. Furet and D. Fabbro, A small synthetic peptide, which inhibits the p53-hdm2 interaction, stimulates the p53 pathway in tumour cell lines, J Mol Biol 299 (2000), 245-253.
152. S.A. Kane, C.A. Fleener, Y.S. Zhang, L.J. Davis, A.L. Musselman and P.S. Huang, Development of a binding assay for p53/HDM2 by using homogeneous time- resolved fluorescence, Anal Biochem 278 (2000), 29-38.
153. Z. Lai, K.R. Auger, C.M. Manubay and R.A. Copeland, Thermodynamics of p53 binding to hdm2(1-126): effects of phosphorylation and p53 peptide length, Arch Biochem Biophys 381 (2000), 278-284.
154. R. Stoll, C. Renner, S. Hansen et al., Chalcone derivatives antagonize interactions between the human oncoprotein MDM2 and p53, Biochemistry 40 (2001), 336-344.